Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Accumulated Expenses (2019 - 2025)

Cyclerion Therapeutics has reported Accumulated Expenses over the past 7 years, most recently at $351000.0 for Q3 2025.

  • Quarterly results put Accumulated Expenses at $351000.0 for Q3 2025, up 8.33% from a year ago — trailing twelve months through Sep 2025 was $351000.0 (up 8.33% YoY), and the annual figure for FY2024 was $283000.0, down 64.54%.
  • Accumulated Expenses for Q3 2025 was $351000.0 at Cyclerion Therapeutics, up from $72000.0 in the prior quarter.
  • Over the last five years, Accumulated Expenses for CYCN hit a ceiling of $2.6 million in Q3 2022 and a floor of $50000.0 in Q1 2025.
  • Median Accumulated Expenses over the past 5 years was $336000.0 (2021), compared with a mean of $628947.4.
  • Biggest five-year swings in Accumulated Expenses: surged 659.76% in 2022 and later plummeted 94.21% in 2023.
  • Cyclerion Therapeutics' Accumulated Expenses stood at $266000.0 in 2021, then surged by 204.14% to $809000.0 in 2022, then decreased by 1.36% to $798000.0 in 2023, then plummeted by 64.54% to $283000.0 in 2024, then rose by 24.03% to $351000.0 in 2025.
  • The last three reported values for Accumulated Expenses were $351000.0 (Q3 2025), $72000.0 (Q2 2025), and $50000.0 (Q1 2025) per Business Quant data.